MarketCap
Facebook
X
TelegramAdamas Pharmaceuticals, Inc. Total Current Liabilities 2011-2026 | ADMS
Annual Total Current Liabilities Adamas Pharmaceuticals, Inc.
| 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| 34.9 M | 26.9 M | 24.3 M | 16.6 M | 9.74 M | 11.8 M | 12.5 M | 4.22 M | 38.5 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 38.5 M | 4.22 M | 19.9 M |
Total Current Liabilities of other stocks in the Biotechnology industry
| Issuer | Total Current Liabilities | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Aligos Therapeutics
ALGS
|
21.2 M | $ 8.65 | 0.16 % | $ 85.5 M |  USA |
 |
Allakos
ALLK
|
36.6 M | - | - | $ 28.6 M | USA |
 |
Anavex Life Sciences Corp.
AVXL
|
5.04 M | $ 3.23 | 3.7 % | $ 275 M | USA |
 |
Aptinyx
APTX
|
6.29 M | - | -39.0 % | $ 4.57 M | USA |
 |
Aravive
ARAV
|
22.1 M | - | -13.39 % | $ 1.45 M | USA |
 |
I-Mab
IMAB
|
576 M | - | - | $ 866 M |  China |
 |
AlloVir
ALVR
|
9.71 M | - | 4.14 % | $ 49.1 M | USA |
 |
Applied Molecular Transport
AMTI
|
15.1 M | - | - | $ 10.1 M | USA |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
1.62 B | - | - | $ 40.3 B | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
11 M | - | -2.5 % | $ 5.88 M | USA |
 |
Applied Therapeutics
APLT
|
71.2 M | - | - | $ 8.42 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
1.77 M | - | -1.52 % | $ 24.7 M | USA |
 |
BeiGene, Ltd.
BGNE
|
1.83 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Cabaletta Bio
CABA
|
50.2 M | $ 3.22 | 0.47 % | $ 324 M | USA |
 |
bluebird bio
BLUE
|
200 M | - | - | $ 546 M | USA |
 |
Amphastar Pharmaceuticals
AMPH
|
158 M | $ 21.57 | 0.98 % | $ 1.01 B | USA |
 |
Checkpoint Therapeutics
CKPT
|
20.1 M | - | - | $ 169 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
556 M | - | - | - |  Russia |
 |
Adverum Biotechnologies
ADVM
|
22.9 M | - | - | $ 86.2 M | USA |
 |
Advaxis
ADXS
|
25 M | - | -9.65 % | $ 45.9 M | USA |
 |
Clearside Biomedical
CLSD
|
6.81 M | - | - | $ 25.3 M | USA |
 |
AgeX Therapeutics
AGE
|
3.56 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aeglea BioTherapeutics
AGLE
|
58.7 M | - | - | $ 1.01 B | USA |
 |
Akebia Therapeutics
AKBA
|
163 M | $ 1.54 | 4.76 % | $ 396 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
25.2 M | - | - | $ 26.5 M | USA |
|
Forte Biosciences
FBRX
|
20.8 M | $ 33.36 | 9.02 % | $ 432 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
2.73 M | $ 3.05 | 4.45 % | $ 5.02 M |  Israel |
 |
Aquestive Therapeutics
AQST
|
47.6 M | $ 4.18 | -0.24 % | $ 447 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
130 M | $ 25.16 | 4.29 % | $ 3.2 B | USA |
 |
Chimerix
CMRX
|
18.4 M | - | - | $ 756 M | USA |
 |
Concert Pharmaceuticals
CNCE
|
16.1 M | - | - | $ 401 M | USA |
 |
AIkido Pharma
AIKI
|
1.61 M | - | 1.93 % | $ 17.4 M | USA |
 |
Celldex Therapeutics
CLDX
|
51 M | $ 33.24 | 1.99 % | $ 2.21 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
73.4 M | $ 1.48 | 0.34 % | $ 394 M |  Britain |
 |
Aptose Biosciences
APTO
|
9.31 M | - | -45.71 % | $ 1.2 M |  Canada |
 |
Cidara Therapeutics
CDTX
|
49.6 M | - | - | $ 1.41 B | USA |
 |
Galectin Therapeutics
GALT
|
8.03 M | $ 2.44 | 3.83 % | $ 156 M | USA |
 |
AVROBIO
AVRO
|
6.35 M | - | 1083.1 % | $ 745 M | USA |
 |
CNS Pharmaceuticals
CNSP
|
4.1 M | $ 2.59 | 6.37 % | $ 1.15 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
7.54 M | - | - | $ 7.46 M | Israel |